AKAN Stock Crashes 32% – Why This Short Seller Sees ‘Zero Fundamental Value’ In Akanda’s Shares

• Fugazi raised dilution concerns, highlighting 10 capital raises over the past four years.
• The current tight supply setup leaves the stock vulnerable to a sharp downside move at any time, the report added.
• AKAN shares have soared more than 1,600%, fueled by optimism around marijuana reclassification news last month.

Shares of Akanda Corp. (AKAN) plunged more than 32% on Monday, snapping a four-session super rally, after a short report highlighted the stock’s “zero fundamental value,” dragging investor sentiment.

AKAN shares have risen sharply since last month’s marijuana reclassification news, surging a mammoth 1,656% since April 22, including a blistering 371% run over the past four sessions.

However, Fugazi Research said in a Monday report that at current levels, the stock appears to be trading more on its recent price momentum than on the strength of its underlying business.

Fugazi: AKAN Shares Are ‘Uninvestable’ 

Fugazi noted that Akanda is no longer in the weed business and is instead “installing fiber-optic towers in Mexico.” However, many momentum-driven traders chasing the “next hot weed stock” appear unaware that the company has shifted its focus entirely, it said.

Concerns have also been raised about repeated shareholder dilution, with 10 capital raises over the past four years. The current tight supply setup leaves the stock vulnerable to a sharp downside move at any time, with the potential for abrupt price swings.

Recent financial filings paint a consistent picture, Fugazi added. The legacy cannabis business has been phased out; telecom operations remain relatively small; cash resources are limited; and liabilities have grown beyond what the current business can comfortably support.

“We consider AKAN’s shares to be uninvestable and to have zero fundamental value,” the report read.

What Sparked Akanda’s Breakout Rally?

The stock surge followed a major policy shift, with the U.S. Department of Justice (DOJ) moving to reclassify medical marijuana as a less restrictive drug after an executive order from President Donald Trump.

Although this does not legalize marijuana, the reclassification is expected to reduce regulatory hurdles, offer tax benefits to licensed operators, and encourage further research. It could also accelerate rulemaking, improve patient access, and bring tighter oversight to medical marijuana programs across the U.S.

Retail Traders Expect Stock To Tank

The stock continued to attract retail attention with sentiment on Stocktwits trending in the ‘extremely bullish’ territory over the past 24 hours, while message volumes on the platform surged 115%.

However, chatter was largely negative, with one user stating that the stock crashes hard after every rally due to its lack of fundamental strength.

Another user expects the stock to fall to $20 before its quarterly earnings. It is currently trading around $40.8.

On April 13, Akanda implemented a 1-for-4.5 reverse stock split.

Read also: CLNN Stock Rises 8% – Here’s What The FDA Update Means For Clene’s ALS Treatment 

For updates and corrections, email newsroom[at]stocktwits[dot]com.